Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Amicus Therapeutics Inc

Healthcare US FOLD

NoneUSD
0.00(0%)

Last update at 2026-05-28T22:01:19.292091Z

Day Range

--
LowHigh

52 Week Range

5.5114.48
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap4540.45M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA41.95M
  • Revenue TTM634.21M
  • Revenue Per Share TTM2.06
  • Gross Profit TTM 561.28M
  • Diluted EPS TTM-0.09

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 0.19M -28.75600M -150.10100M -242.03900M -241.55400M
Minority interest - - - - -
Net income -27.11000M -56.10600M -151.58400M -236.56800M -250.46000M
Selling general administrative 383.49M 323.38M 259.31M 214.12M 199.22M
Selling and marketing expenses - - - - -
Gross profit 553.82M 475.35M 362.03M 290.63M 271.05M
Reconciled depreciation 7.46M 8.55M 7.00M 5.34M 6.21M
Ebit 46.35M 20.84M -99.95200M -204.42600M -199.92000M
Ebitda 53.81M 29.39M -92.07900M -191.88400M -196.10300M
Depreciation and amortization 7.46M 8.55M 7.87M 12.54M 3.82M
Non operating income net other - - - 7.20M -2.64900M
Operating income 34.49M 24.88M -77.21100M -204.42600M -199.92000M
Other operating expenses 599.72M 503.42M 476.57M 533.66M 505.43M
Interest expense 46.16M 49.60M 50.15M 37.12M 32.47M
Tax provision 27.30M 27.35M -14.91400M -5.47100M 8.91M
Interest income 3.32M 5.41M 7.38M 3.02M 0.51M
Net interest income -42.84200M -44.19100M -41.03800M -34.09500M -31.96200M
Extraordinary items - - - - -
Non recurring - - - 6.62M -
Other items - - - - -
Income tax expense 27.30M 27.35M 1.48M -5.47100M 8.91M
Total revenue 634.21M 528.29M 399.36M 329.23M 305.51M
Total operating expenses 519.33M 450.48M 439.24M 495.06M 470.97M
Cost of revenue 80.39M 52.94M 37.33M 38.60M 34.47M
Total other income expense net -34.30000M -53.63200M -72.89000M -37.61300M -41.63400M
Discontinued operations - - - - -
Net income from continuing ops -27.11000M -56.10600M -173.60600M -236.56800M -250.46000M
Net income applicable to common shares - - - -236.56800M -250.46000M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 949.87M 785.03M 777.88M 724.17M 905.14M
Intangible assets 13.91M 17.20M 20.49M 23.00M 23.00M
Earning assets - - - - -
Other current assets 38.51M 34.91M 49.53M 40.21M 34.85M
Total liab 675.63M 590.99M 617.71M 601.12M 597.77M
Total stockholder equity 274.24M 194.04M 160.17M 123.05M 307.37M
Deferred long term liab - - - 9.60M 10.84M
Other current liab 200.46M 109.19M 131.81M 110.11M 117.05M
Common stock 3.04M 2.94M 2.92M 2.81M 2.81M
Capital stock 3.04M 2.94M 2.92M 2.81M 2.81M
Retained earnings -2767.29000M -2740.18000M -2684.07400M -2532.49000M -2295.92200M
Other liab - - - 18.53M 19.08M
Good will 197.80M 197.80M 197.80M 197.80M 197.80M
Other assets - - - 42.24M 47.43M
Cash 214.01M 213.75M 246.99M 148.81M 245.20M
Cash and equivalents - - - - -
Total current liabilities 237.83M 148.70M 167.69M 139.02M 145.97M
Current deferred revenue - - 12.43M 4.94M -
Net debt 269.31M 229.89M 198.06M 303.31M 194.93M
Short term debt 8.74M 8.46M 8.32M 8.55M 7.41M
Short long term debt - - - - -
Short long term debt total 483.32M 443.64M 445.06M 452.12M 440.13M
Other stockholder equity 3014.39M 2926.19M 2836.02M 2664.83M 2595.50M
Property plant equipment - - - 30.78M 42.50M
Total current assets 676.17M 504.74M 483.06M 423.82M 596.83M
Long term investments - - - - -
Net tangible assets - - - -97.75000M 86.57M
Short term investments 79.53M 36.19M 39.21M 144.78M 237.30M
Net receivables 115.31M 101.10M 87.63M 66.20M 52.67M
Long term debt 392.66M 390.11M 387.86M 391.99M 389.36M
Inventory 228.82M 118.78M 59.70M 23.82M 26.82M
Accounts payable 28.63M 12.95M 15.12M 15.41M 21.51M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 24.11M 5.09M 5.31M -12.10500M 4.98M
Additional paid in capital - - - - -
Common stock total equity - - - 2.81M 2.81M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -2532.49000M -2295.92200M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 13.74M 13.64M 15.47M 14.30M 24.43M
Deferred long term asset charges - - - - -
Non current assets total 273.70M 280.30M 294.82M 300.35M 308.31M
Capital lease obligations 49.70M 53.53M 57.20M 60.13M 50.77M
Long term debt total - - - 391.99M 389.36M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -43.13600M -0.56000M 55.32M 92.67M 82.64M
Change to liabilities - - - -6.37700M 7.43M
Total cashflows from investing activities -46.43200M -0.56000M - 92.32M 78.76M
Net borrowings -0.27200M -0.09700M - -0.28300M -0.47900M
Total cash from financing activities 0.61M 5.12M 61.68M -7.46300M 212.07M
Change to operating activities - - - -10.83000M -18.88900M
Net income -27.11000M -56.10600M -151.58400M -236.56800M -250.46000M
Change in cash 0.60M -33.36100M 98.18M -96.34100M 83.29M
Begin period cash flow 216.72M 250.08M 148.81M 249.46M 166.16M
End period cash flow 217.32M 216.72M 246.99M 153.12M 249.46M
Total cash from operating activities 33.15M -33.89100M -69.09100M -166.57500M -202.49100M
Issuance of capital stock 0.00000M 19.57M 63.11M 2.35M 199.75M
Depreciation 2.57M 8.55M 7.87M 5.34M 6.21M
Other cashflows from investing activities - - - 3.41M -
Dividends paid - - - 4.31M 15.01M
Change to inventory -111.48300M -73.65200M -44.61400M -5.34300M -7.79000M
Change to account receivables -5.86000M -19.48400M -20.10800M -17.33000M -8.18900M
Sale purchase of stock - - -17.92000M -11.49000M -15.00900M
Other cashflows from financing activities -18.32300M -22.02500M -20.57300M 4.31M 42.82M
Change to netincome - - - 77.60M 64.64M
Capital expenditures 3.30M 3.55M 7.44M 3.77M 3.88M
Change receivables - - - -17.33000M -8.18900M
Cash flows other operating - - - 13.47M -16.82400M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -81.72200M 88.34M
Change in working capital -39.63300M -98.94300M -47.99000M -39.88000M -18.58500M
Stock based compensation 87.41M 84.91M 86.08M 76.51M 57.84M
Other non cash items 9.91M 27.71M 41.47M 28.01M 2.47M
Free cash flow 29.85M -37.44400M -76.53100M -170.34100M -206.37500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
FOLD
Amicus Therapeutics Inc		 - -% - - 30.49 7.16 16.56 7.40 87.17
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Amicus Therapeutics Inc

47 Hulfish Street, Princeton, NJ, United States, 08542

Key Executives

Name Title Year Born
Mr. John F. Crowley Exec. Chairman 1967
Mr. Bradley L. Campbell M.B.A. CEO, Pres & Director 1976
Ms. Daphne E. Quimi CPA, M.B.A. Chief Financial Officer 1966
Ms. Ellen S. Rosenberg Chief Legal Officer & Corp. Sec. 1963
Mr. David M. Clark Chief People Officer 1975
Ms. Samantha Prout VP, Global Controller & Principal Accounting Officer 1978
Dr. Jill Weimer Ph.D. Chief Science Officer NA
Andrew Faughnan Sr. Director of Investor Relations NA
Mr. Patrik S. Florencio Sr. VP, Global Chief Compliance & Risk Officer NA
Ms. Diana Moore Head of Global Corp. Communications NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.